1. Home
  2. |Insights
  3. |OMB Proposes a 21st Century Federal Grants Regulatory Structure

OMB Proposes a 21st Century Federal Grants Regulatory Structure

Client Alert | less than 1 min read | 02.04.13

On February 1, 2013, OMB published a proposal to consolidate eight existing OMB circulars, establishing uniform standards for administrative requirements, cost principles, and audit requirements for all grants and cooperative agreements. While OMB's primary focus appears to be on consolidating existing federal financial participation regulations, OMB also included a "cross-walk" to the current Circular A-110 identifying the proposed policy changes and updates if the proposal were adopted.


Contacts

Insights

Client Alert | 7 min read | 09.14.26

AI in Life Sciences: Ten Legal Considerations and Risks of AI Use in Drug Discovery and Development

Over the past several years, the biopharmaceutical industry has embraced artificial intelligence and machine learning (AI/ML) in near lockstep with the pace of AI/ML innovations. Today, industry leaders are using AI/ML to, among other things: discover and assess biological pathways, target chemical structures and sequences; design proteins; model pre-clinical and clinical trials; recruit and screen potential patient populations; evaluate clinical trial results and biomarker data; prepare regulatory filings; and manage supply chains. Deployment of new AI/ML models promises extraordinary advances in pharmaceutical development. However, as with any technological and scientific advances, the use of AI/ML also poses substantial legal risks that life sciences companies need to consider and proactively manage. ...

View All Insights